-
China Biopharma Posts 216% Revenue Increase, Eyes US$10 Million in 2007 with Vaccine Distribution and New Treatments
•
China Biopharma Corporation, trading on the OTC Bulletin Board under the symbol (CBPC.OB), announced a remarkable leap in its financial results for 2006 on April 2nd. The company reported a staggering 216% increase in total revenues, surging from US$380,519 in 2005 to US$1.2 million in 2006. This revenue growth was…
-
India Launches Anti-Dumping Campaign Against Chinese Vitamin B12 and Ceftriaxone Sodium Producers
•
In a strategic response to India’s Ministry of Commerce and Industry’s (MOFCOM) anti-dumping ruling against Chinese vitamin A palmitate producers, Indian pharmaceutical firms have initiated a new campaign on March 13. This time, the focus is on China’s manufacturers of vitamin B12 and ceftriaxone sodium, with customs codes 29362610 and…
-
Novartis Sees 15% Global Sales Growth and Significant Investment in China for 2006
•
Novartis (NYSE: NVS), a multinational pharmaceutical giant, has reported a robust sales revenue of nearly US$275.7 million in the China market for the year 2006. This figure comes as part of a broader global sales increase of 15%, propelling the company’s total global revenue to US$37 billion, with net income…
-
China’s Western Pharmaceutical Exports Soar 23% in 2006, Led by Antibiotics
•
The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE) has reported a robust surge in China’s export values for Western pharmaceutical preparations in 2006. The year-on-year growth rate reached a significant 23%, with the total value amassing to US$504 million. Among the various categories,…
